Advances in therapeutic options for portal hypertension.

abstract：:Crohn's disease (CD) is a chronic relapsing and remitting disorder of the gastrointestinal tract with no known cure. The inflammation that drives the disease can lead to debilitating symptoms and a number of complications that may lead to surgery. The introduction of biologic therapy a decade ago has offered a new opt...

journal_title：Therapeutic advances in gastroenterology

authors： Panaccione R,Ghosh S

更新日期：2010-05-01 00:00:00

abstract：:Helicobacter pylori (H. pylori) are gram-negative bacteria that selectively colonizes the gastric mucosa. The prevalence of H. pylori infection varies from 20 to 50% in industrialized countries to over 80% in developing countries. The infection may persist lifelong without specific treatment. Prolonged infection and i...

journal_title：Therapeutic advances in gastroenterology

authors： Lee YC,Liou JM,Wu MS,Wu CY,Lin JT

更新日期：2008-09-01 00:00:00

abstract：BACKGROUND:Patients with Barrett's esophagus (BE) are commonly treated with proton-pump inhibitors (PPIs) to minimize the exposure of esophageal mucosa to stomach acid. However, the use of these medications can lead to significant hypergastrinemia in a subset of patients, which is concerning due to the known tumorigeni...

journal_title：Therapeutic advances in gastroenterology

authors： Green DA,Mlynarczyk CM,Vaccaro BJ,Capiak KM,Quante M,Lightdale CJ,Abrams JA

更新日期：2011-03-01 00:00:00

abstract：Background:The clinical outcome of patients with obscure gastrointestinal bleeding (OGIB) during antithrombotic drug therapy has not been fully investigated. Methods:Patients who underwent video capsule endoscopy (VCE) for the investigation of OGIB at Okayama University Hospital from January 2009 to March 2016 were en...

journal_title：Therapeutic advances in gastroenterology

authors： Kono Y,Kawano S,Okamoto Y,Obayashi Y,Baba Y,Sakae H,Abe M,Gotoda T,Inokuchi T,Kanzaki H,Iwamuro M,Kawahara Y,Okada H

更新日期：2018-01-14 00:00:00

abstract：:The treatment of hepatocellular carcinoma (HCC) remains a challenge, with 1- and 3-year survival rates of 20% and 5%, respectively, and a median survival of 8 months. However, a better understanding of the pathogenesis of HCC, and advances in targeted molecular therapies provide physicians treating this disease with n...

journal_title：Therapeutic advances in gastroenterology

authors： Olsen SK,Brown RS,Siegel AB

更新日期：2010-01-01 00:00:00

abstract：Background:The incidence of Clostridioides difficile infection (CDI) is increasing in the general population. Data on the epidemiology of CDI in peripartum women - a highly vulnerable patient population - is scarce. The objective of this study was to report the incidence of CDI in peripartum women. Methods:A single-ce...

journal_title：Therapeutic advances in gastroenterology

authors： Saha S,Pardi R,Theiler RN,Pardi DS,Khanna S

更新日期：2020-07-27 00:00:00

abstract：BACKGROUND:Few studies have compared early gastric cancer (EGC) outcomes according to sex and age. METHODS:We retrospectively reviewed 2085 patients who underwent curative gastrectomy for EGC between 1989 and 2000. Prognosis and risk factors for nodal involvement were evaluated according to sex and age. RESULTS:Male ...

journal_title：Therapeutic advances in gastroenterology

authors： Suh DD,Oh ST,Yook JH,Kim BS,Kim BS

更新日期：2017-02-01 00:00:00

abstract：:Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programmed death ligand-1 (...

journal_title：Therapeutic advances in gastroenterology

authors： Liu X,Yang Z,Latchoumanin O,Qiao L

更新日期：2016-11-01 00:00:00

abstract：Background:Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn's disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this study was to evaluate postoperative complications and perioperative safety in VDZ-tr...

journal_title：Therapeutic advances in gastroenterology

authors： Kotze PG,Ma C,Mckenna N,Almutairdi A,Kaplan GG,Raffals LE,Loftus EV Jr,Panaccione R,Lightner AL

更新日期：2018-06-21 00:00:00

abstract：:Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant costs. Multiple cli...

journal_title：Therapeutic advances in gastroenterology

authors： Kopylov U,Seidman E

更新日期：2016-07-01 00:00:00

abstract：BACKGROUND:Self-expandable metal stent (SEMS) placement is a minimally invasive treatment for palliation of malignant colorectal strictures and as a bridge to surgery. However, the use of SEMS for benign colorectal diseases is controversial. The purpose of this retrospective study is to evaluate the efficacy and safety...

journal_title：Therapeutic advances in gastroenterology

authors： Cereatti F,Fiocca F,Dumont JL,Ceci V,Vergeau BM,Tuszynski T,Meduri B,Donatelli G

更新日期：2016-03-01 00:00:00

abstract：Background:Postoperative pancreatic collection (POPC) is a frequent complication after pancreatectomy. Although percutaneous drainage (PD) has been the treatment of choice for POPC with encapsulation, endoscopic ultrasound-guided transmural drainage (EUS-TD) was recently reported effective for this condition. The main ...

journal_title：Therapeutic advances in gastroenterology

authors： Tamura T,Kitano M,Kawai M,Tanioka K,Itonaga M,Kawaji Y,Nuta J,Hatamaru K,Yamashita Y,Kitahata Y,Miyazawa M,Hirono S,Okada KI,Yamaue H

更新日期：2019-10-24 00:00:00

abstract：:The incidence and prevalence of ulcerative colitis (UC) has been reported to be rising in newly industrialised regions, such as Latin America. Here, we review data from published studies reporting demographics and clinical aspects of UC in Latin America to further understand epidemiology and disease burden. The incide...

journal_title：Therapeutic advances in gastroenterology

authors： Kotze PG,Steinwurz F,Francisconi C,Zaltman C,Pinheiro M,Salese L,Ponce de Leon D

更新日期：2020-07-09 00:00:00

abstract：:Clostridium difficile was first described as a cause of diarrhea in 1978 and in the last three decades has reached an epidemic state with increasing incidence and severity in both healthcare and community settings. There also has been a rise in severe outcomes from C. difficile infection (CDI). There have been tremend...

journal_title：Therapeutic advances in gastroenterology

authors： Khanna S,Pardi DS

更新日期：2014-03-01 00:00:00

abstract：BACKGROUND:Some chronic hepatitis C virus (HCV), genotype 1 infected patients treated with direct antiviral agents (DAAs) remain viremic at end of treatment (EOT+), yet go on to achieve sustained virological response 12 weeks after completion of therapy (SVR12). The incidence of EOT+/SVR in patients with genotype 1 and...

journal_title：Therapeutic advances in gastroenterology

authors： Malespin M,Benyashvili T,Uprichard SL,Perelson AS,Dahari H,Cotler SJ

更新日期：2017-01-01 00:00:00

abstract：:Pancreatic neuroendocrine tumors (pNETs) are relatively rare malignancies. With secretory tumors such as insulinomas, vasoactive intestinal peptideomas, and gastrinomas, the hormone produced causes the symptom complex (e.g. hypoglycemia, peptic ulcer disease). With nonsecretory NETs, the clinical condition is determin...

journal_title：Therapeutic advances in gastroenterology

authors： Vinik AI,Raymond E

更新日期：2013-09-01 00:00:00

abstract：Background:Pharmacotherapy, including prokinetics and proton pump inhibitors for functional dyspepsia (FD) have limited effectiveness, and their safety has been recently questioned. Chinese herbal medicine (CHM) could be considered as an alternative. A systematic review (SR) of SRs was performed to evaluate the potenti...

journal_title：Therapeutic advances in gastroenterology

authors： Chu MHK,Wu IXY,Ho RST,Wong CHL,Zhang AL,Zhang Y,Wu JCY,Chung VCH

更新日期：2018-07-16 00:00:00

abstract：:In recent years, mucosal healing has emerged as a key therapeutic goal in the clinical management of patients with Crohn's disease, as it has been associated with improved long-term clinical outcomes. With the vast improvements in endoscopic imaging techniques and the increase in available treatment options, which rep...

journal_title：Therapeutic advances in gastroenterology

authors： Klenske E,Bojarski C,Waldner M,Rath T,Neurath MF,Atreya R

更新日期：2019-06-14 00:00:00

abstract：Background:Nonalcoholic fatty liver disease (NAFLD) is correlated with low-grade inflammation and dietary habits. Until today, there have been limited epidemiologic data assessing the role of diet's inflammatory potential on NAFLD. The aim was to evaluate the relationship between an anti-inflammatory diet, as reflected...

journal_title：Therapeutic advances in gastroenterology

authors： Tyrovolas S,Panagiotakos DB,Georgousopoulou EN,Chrysohoou C,Skoumas J,Pan W,Tousoulis D,Pitsavos C

更新日期：2019-06-23 00:00:00

abstract：:Crohn's disease and ulcerative colitis are chronic inflammatory disorders of the gastrointestinal tract. Treatment options include biologic therapies; however, a proportion of patients lose response to biologics, partly due to the formation of anti-drug antibodies (ADAbs). Concomitant immunosuppressive agents reduce t...

journal_title：Therapeutic advances in gastroenterology

authors： Vermeire S,Gils A,Accossato P,Lula S,Marren A

更新日期：2018-01-21 00:00:00

abstract：Background:Variability in glucagon-like peptide (GLP)-1 and GLP-2 plasma concentrations has been suggested in Celiac disease (CD), with inconclusive results. We assessed the association between serum levels of GLP-1 and GLP-2 and their duodenal receptor expression in children with and without CD. Methods:This was a tw...

journal_title：Therapeutic advances in gastroenterology

authors： Rachmiel M,Ben-Yehudah G,Shirin H,Broide E

更新日期：2019-04-17 00:00:00

abstract：:In 2010, four independent groups almost simultaneously reported the association of the novel interleukin-1 (IL-1) family member, IL-33, with inflammatory bowel disease (IBD). The findings were remarkably consistent and demonstrated that IL-33 is markedly upregulated in, and specific to, ulcerative colitis (UC). In add...

journal_title：Therapeutic advances in gastroenterology

authors： Pastorelli L,De Salvo C,Cominelli MA,Vecchi M,Pizarro TT

更新日期：2011-09-01 00:00:00

abstract：Background and Aims:Efficacy of adalimumab in Crohn's disease (CD) has not been shown in China. The aim of this study was to evaluate the efficacy and safety of adalimumab in Chinese patients with CD. Methods:This 26-week, multicenter, phase III study evaluated patients with moderately to severely active CD and elevat...

journal_title：Therapeutic advances in gastroenterology

authors： Chen B,Gao X,Zhong J,Ren J,Zhu X,Liu Z,Wu K,Kalabic J,Yu Z,Huang B,Kwatra N,Doan T,Robinson AM,Chen MH

更新日期：2020-07-16 00:00:00

abstract：:Severe acute pancreatitis (SAP) is a critical abdominal disease associated with high death rates. A systemic inflammatory response promotes disease progression, resulting in multiple organ dysfunction. The functions of neutrophils in the pathology of SAP have been presumed traditionally to be activation of chemokine a...

journal_title：Therapeutic advances in gastroenterology

authors： Hu J,Kang H,Chen H,Yao J,Yi X,Tang W,Wan M

更新日期：2020-11-24 00:00:00

abstract：:Endoscopic argon plasma coagulation and bipolar electrocautery are currently preferred treatments for chronic radiation proctitis, but ulcerations and strictures frequently occur. Radiofrequency ablation (RFA) has been successful for mucosal ablation in the esophagus. Here we report the efficacy of RFA with the BarRx ...

journal_title：Therapeutic advances in gastroenterology

authors： Zhou C,Adler DC,Becker L,Chen Y,Tsai TH,Figueiredo M,Schmitt JM,Fujimoto JG,Mashimo H

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D. The objective of this secondary analysis was to evaluate rifaximin retreatment on IBS-related QOL in patients with IBS-D. METHODS:Patients received o...

journal_title：Therapeutic advances in gastroenterology

authors： Cash BD,Pimentel M,Rao SSC,Weinstock L,Chang L,Heimanson Z,Lembo A

更新日期：2017-09-01 00:00:00

abstract：Background:In patients with a large, unresectable hepatocellular carcinoma (HCC), the primary recommendation is for transarterial chemoembolization (TACE) but used alone TACE is not typically curative. Combinations of TACE followed in a delayed fashion by single-applicator thermal ablation have also been suboptimal. As...

journal_title：Therapeutic advances in gastroenterology

authors： Zhang TQ,Huang ZM,Shen JX,Chen GQ,Shen LJ,Ai F,Gu YK,Yao W,Zhang YY,Guo RP,Chen MS,Huang JH

更新日期：2019-08-21 00:00:00

abstract：:Nonalcoholic fatty liver disease (NAFLD) is becoming the most common cause of chronic liver disease in the developing world, found in 17-30% of the population in Western countries and 2-4% worldwide. Defined as the accumulation of fatty acid content greater than 5% of liver weight, NAFLD is a spectrum of disease rangi...

journal_title：Therapeutic advances in gastroenterology

authors： Kneeman JM,Misdraji J,Corey KE

更新日期：2012-05-01 00:00:00

abstract：Background:Recently the American Society for Gastrointestinal Endoscopy addressed the 'resect and discard' strategy, determining that accurate in vivo differentiation of colorectal polyps (CP) is necessary. Previous studies have suggested a promising application of artificial intelligence (AI), using deep learning in o...

journal_title：Therapeutic advances in gastroenterology

authors： Ozawa T,Ishihara S,Fujishiro M,Kumagai Y,Shichijo S,Tada T

更新日期：2020-03-20 00:00:00

abstract：:Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases and hepatocellular carcinoma (HCC) worldwide. In the past few years, anti-HCV therapies have undergone a revolution with the approval of multiple direct-acting antivirals (DAAs), which enable interferon-free treatments with consider...

journal_title：Therapeutic advances in gastroenterology

authors： Crouchet E,Wrensch F,Schuster C,Zeisel MB,Baumert TF

更新日期：2018-03-21 00:00:00